ATE423574T1 - Dominant-negativer plb mutant zur behandlung der herzerkrankungen - Google Patents

Dominant-negativer plb mutant zur behandlung der herzerkrankungen

Info

Publication number
ATE423574T1
ATE423574T1 AT01971139T AT01971139T ATE423574T1 AT E423574 T1 ATE423574 T1 AT E423574T1 AT 01971139 T AT01971139 T AT 01971139T AT 01971139 T AT01971139 T AT 01971139T AT E423574 T1 ATE423574 T1 AT E423574T1
Authority
AT
Austria
Prior art keywords
dominant
negative
treatment
heart diseases
plb
Prior art date
Application number
AT01971139T
Other languages
English (en)
Inventor
Kenneth Chien
Masahiko Hoshijima
John Ross
Yasuhiro Ikeda
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE423574T1 publication Critical patent/ATE423574T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01971139T 2000-09-11 2001-09-11 Dominant-negativer plb mutant zur behandlung der herzerkrankungen ATE423574T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23182100P 2000-09-11 2000-09-11

Publications (1)

Publication Number Publication Date
ATE423574T1 true ATE423574T1 (de) 2009-03-15

Family

ID=22870756

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01971139T ATE423574T1 (de) 2000-09-11 2001-09-11 Dominant-negativer plb mutant zur behandlung der herzerkrankungen

Country Status (8)

Country Link
US (1) US7399750B2 (de)
EP (1) EP1317289B1 (de)
AT (1) ATE423574T1 (de)
AU (1) AU2001291063A1 (de)
CA (1) CA2422078C (de)
DE (1) DE60137778D1 (de)
ES (1) ES2320975T3 (de)
WO (1) WO2002022177A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745416B2 (en) * 1995-04-11 2010-06-29 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
US20090239940A1 (en) * 1997-07-22 2009-09-24 Del Monte Federica Treating heart failure and ventricular arrhythmias
JP4197614B2 (ja) 2001-02-07 2008-12-17 ヴァンダービルト ユニヴァーシティ 細胞性免疫応答を増強するためのプロアポトーシス細菌ワクチン
US7618948B2 (en) 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7994149B2 (en) 2003-02-03 2011-08-09 Medtronic, Inc. Method for treatment of Huntington's disease through intracranial delivery of sirna
WO2005023292A1 (en) * 2003-09-03 2005-03-17 The General Hospital Corporation Methods of treating restenosis
US20060198825A1 (en) * 2005-03-03 2006-09-07 Kaemmerer William F Reagents, methods and systems to suppress phospholamban expression
US9133517B2 (en) 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
CN101548015A (zh) * 2005-11-15 2009-09-30 范德比尔特大学 用于递送和表达抗原的促凋亡细菌和组合物
CA2638913A1 (en) 2006-02-10 2007-09-07 The University Of Cincinnati Phosphatase inhibitor protein-1 as a regulator of cardiac function
US20070265221A1 (en) * 2006-05-09 2007-11-15 Weiss Robert G Methods to improve creatine kinase metabolism and contractile function in cardiac muscle for the treatment of heart failure
US9273356B2 (en) 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
GB2437893A (en) * 2006-07-25 2007-11-07 Celladon Corp Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
US9375440B2 (en) 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
WO2008137681A2 (en) * 2007-05-02 2008-11-13 Intrexon Corporation Pp1 ligands
WO2009105135A1 (en) 2008-02-19 2009-08-27 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
US20110144028A1 (en) * 2009-12-11 2011-06-16 Vinod Sharma Modulating cellular electrophysiology

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US6884600B1 (en) 1996-03-30 2005-04-26 Medical Research Council London Protein phosphatase-1 catalytic subunit interactions
FR2753722A1 (fr) 1996-09-26 1998-03-27 Smithkline Beecham Lab Procede de detection de modulateurs de relaxation cardiaque et modulateurs ainsi obtenus
US5968959A (en) 1997-12-12 1999-10-19 Orion Corporation Method for the prevention and treatment of stunned myocardium
EP1126866B1 (de) * 1998-11-02 2007-02-07 The Regents of The University of California Eine mutante phospholamban moleküle und deren verwendung zur behandlung von herzkrankheiten und herzversagen

Also Published As

Publication number Publication date
CA2422078A1 (en) 2002-03-21
US20020032167A1 (en) 2002-03-14
US7399750B2 (en) 2008-07-15
WO2002022177A2 (en) 2002-03-21
DE60137778D1 (de) 2009-04-09
HK1056316A1 (en) 2004-02-13
ES2320975T3 (es) 2009-06-01
AU2001291063A1 (en) 2002-03-26
EP1317289B1 (de) 2009-02-25
EP1317289A2 (de) 2003-06-11
WO2002022177A3 (en) 2002-11-28
CA2422078C (en) 2011-08-09

Similar Documents

Publication Publication Date Title
ATE423574T1 (de) Dominant-negativer plb mutant zur behandlung der herzerkrankungen
DE60142840D1 (de) Durch phagendisplay identifizierte zielpeptide des menschen und der maus
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
WO2005030083A3 (en) Methods and products which utilize n-acyl-l-aspartic acid
DE60326077D1 (de) Substituierte 4-(indazol-3-yl)phenole als liganden des oestrogenrezeptors und deren verwendung bei der behandlung von entzündlichen erkrankungen
ATE508635T1 (de) Virusvektoren und ihre verwendung bei therapeutischen methoden
ATE404221T1 (de) Antikörper gegen il6 zur vorbeugung und behandlung entzündlicher darmerkrankungen
DE60131569D1 (de) Genetisch veränderter herpes virus für die behandlung von herz- und gefässerkrankungen
CY1109868T1 (el) Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c
ATE405261T1 (de) Verwendung von castanospermine derivaten in der behandlung von hepatitis c
DK1699480T3 (da) Allogent terapeutisk tumormiddel
NO20043370L (no) N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
ATE446102T1 (de) Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii
ATE427107T1 (de) Eine neue verwendung von deferiprone
DE60129069D1 (de) Hepatitis B Virus Vektoren für Gentherapie
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
TR200200278T2 (tr) Kalsilitik bileşimler
DE60124560D1 (de) Behandlung von angiogenesebezogenen krankheiten mit benzoyl phenylessigsäure derivaten
ATE214101T1 (de) Expression von heterologen genen in menschlichen brustzellen, einschliesslich menschliche brustkarzionomzellen unter der kontrolle von regulatorischen sequenzen von wap oder mmtv
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
NO20033541L (no) Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer
ATE396726T1 (de) Benzothiazole derivate und ihre anwendung in der behandlung von adenosine a2a rezeptor vermittelte krankheiten
DE69803052D1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
NO20030762L (no) Forbedret spesifisitet i behandling av sykdommer
RU2002105561A (ru) Способ физиотерапевтического лечения заболеваний печени

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties